Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920981 | 1.00 | MAPT (0.61) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL27679369 | 0.84 | KDM4E (0.46) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL22207780 | 0.82 | SMN1; SMN2 (0.57) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL9521985 | 0.82 | SMN1; SMN2 (0.47) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL9522833 | 0.81 | MAPT (0.47) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL9522825 | 0.81 | MAPT (0.47) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL23451094 | 0.79 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL10555038 | 0.79 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL9521978 | 0.79 | KDM4E (0.48) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL13611402 | 0.79 | MAPT (0.59) | MAPTKDM4ETHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0301474-B1 | NEW CYSTEINE DERIVATIVES HAVING EXPECTORANT ACTIVITY | MAGIS FARMACEUTICI S.P.A. (IT) | 1993-09-29 | — | — | EP | claimed |
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| US-8263784-B2 | Method for the synthesis of a ramipril intermediate | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2012-09-11 | — | — | US | disclosed |
| US-8105807-B2 | Carbamoylglycine derivatives | DSM IP ASSETS B.V. (NL) | 2012-01-31 | — | — | US | disclosed |
| EP-2200981-B1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS BV (NL) | 2011-12-07 | — | — | EP | disclosed |
| US-20110263871-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| EP-2344455-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | DSM IP Assets B.V. (NL) | 2011-07-20 | — | — | EP | disclosed |
| US-20100221796-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-09-02 | — | — | US | disclosed |
| EP-2200981-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP Assets B.V. (NL) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010049401-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | DSM IP ASSETS B.V. (NL) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009050041-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2009-04-23 | — | — | WO | disclosed |
| EP-0301474-B1 | NEW CYSTEINE DERIVATIVES HAVING EXPECTORANT ACTIVITY | MAGIS FARMACEUTICI S.P.A. (IT) | 1993-09-29 | — | — | EP | disclosed |
| US-4910222-A | Bronchodilator | MAGIS FARMACEUTICI SPA (IT) | 1990-03-20 | — | — | US | disclosed |
| EP-0301474-A2 | New cysteine derivatives having expectorant activity | MAGIS FARMACEUTICI S.P.A. (IT) | 1989-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221796-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DNPEP, ACE, PEPD | MAPT 2574/4885KDM4E 162/4885THRB 4538/4885 |
| US-20110263871-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | POR, CYP11B2, CYP1A2 | MAPT 2815/4885KDM4E 1951/4885THRB 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.